Actinomycin D specifically inhibits the interaction between transcription factor Sp1 and its binding site

• Autorzy: Czyz M. , Gniazdowski M.
• Języki publikacji: EN

Abstrakty

EN

The mode of action of many anticancer drugs involves DNA interactions. We here examine the ability of actinomycin D to alter the specific binding of transcription factors Sp1 and NFκB to their DNA sequences. Employing an electrophoretic mobility shift assay, it is shown that actinomycin D inhibits complex formation between nuclear proteins present in the extracts from stimulated human umbilical vein endothelial cells and the Sp1-binding site. Actinomycin D is also able to induce disruption of preformed DNA-protein complexes, pointing to the importance of an equilibrium of three components: actinomycin D, protein and DNA for drug action. The effect of actinomycin D is sequence-specific, since no inhibition is observed for interaction of nuclear proteins with the NFκB binding site. The results support the view that DNA-binding drugs displaying high sequence-selectivity can exhibit distinct effects on the interaction between DNA and different DNA-binding proteins.

Słowa kluczowe

EN

stimulatory protein 1; DNA-protein interaction; anticancer drug; transcription factor; lipopolysaccharide; actinomycin D; drug; DNA binding; endothelium

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1998
• Tom: 45
• Numer: 1
• Opis fizyczny: p.67-73,fig.

Twórcy

autor

Czyz M.

• Medical University of Lodz, W.Lindleya 6, 90-131 Lodz, Poland

autor

Gniazdowski M.

Bibliografia

• 1. Hurst, H.C. (1996) Transcription factors as drug targets in cancer. Eur. J. Cancer 32A, 1857-1863.
• 2. Laughton, C.A., Jenkins, T.C., Fox, K.R. & Neidle, S. (1990) Interaction of berenil with the tyrT DNA sequence studied by footprints ing and molecular modelling. Implications for the design cf sequence-specific DNA recogni­tion agents. Nucleic Acids Res. 18,4479-4488.
• 3. Churchill, M.E.A., Hayes, J J. & Tullius, T.D. (1990) Detection of drug binding to DNA by hydroxyl radical footprinting. Relationship of distamycin binding sites to DNA structure and positioned nucleosomes of 5S RNA genes of Xenopus. Biochemistry 29. 6043-6050.
• 4. Van Dyke, W.W. & Dervan, P.B. (1983) Chromomycin, mithramycin and olivomycin binding sites on heterogenous DNA. Foot- printing with (methidium propyl-EDTA)iron (II). Biochemistry 22, 2373-2377.
• 5. Stankus, A., Goodisman, J. & D^browiak, J.C. (1992) Quantitative footprinting analysis of the chromomycin A3-DNA interaction. Bio­chemistry 31, 9310-9318.
• 6. Broggini, M. & D'lncalci, M. (1994) Modula­tion of transcription factor-DNA interac­tions by anticancer drugs. Anticancer Drug Design 9. 373-387.
• 7. Bianchi, N., Passadore, M., Rutigliano, C., Feriotto, G., Mischiati, C. & Gambari, R. (1996) Targeting of the Spl binding sites of HIV-1 long terminal repeat with chromomy­cin — Disruption of nuclear factor-DNA complexes and inhibition of in vitro tran­scription. Biochem. Pharmacol. 52, 1489- 1498.
• 8. Muller, J.M., Ziegler-Heitbrock, H.W.L. & Baeuerle, P.A. (1993) Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Im- munobiology 187, 233-256.
• 9. Donahue, J.P., Sugg,N. & Hawiger.J. (1994) The integrin av gene: Identification and characterization of the promoter region. Biochim. Biophys. Acta 1219, 228-232.
• 10. Jaffe, E.A., Nachlman, R.L., Becker, C.G. & Minick, C.R. (1973) Culture of human endo­thelial cells derived from umbilical veins. J. Clin. Invest. 53, 2745-2756.
• 11. Dignam, J.D., Lebovitz, R.M. & Roeder, R.G. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11, 1475-1489.
• 12. Moll, T., Czyz, M., Holzmuller, H., Hofer- Warbinek, R., Wagner, E., Winkler, H.. Bach, F.H. & Hofer.E. (1995) Regulation of the tissue factor promoter in endothelial cells. J. Biol Chem. 270, 3849-3857.
• 13. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) in Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
• 14. Mac Leod, M.C., Powell, K.L., Kuzmin, V.A., Kolbanovskiy, A. & Geacintov, N.E. (1996) In­terference of benzoialpyrene diol epoxide-deoxyguanosine adducts in a GC box with binding of the transcription factor Spl. MoL Carcinogenesis 16, 44-52.
• 15. Gray, P.J. (1995) Sulphur mustards inhibit binding of transcription factor AP 2 in vitro. Nucleic Acids Res. 23, 4378-4382.
• 16. Welch, J.J., Rauscher, F.J. Ill & Beerman.T.A. (1994) Targeting DNA-binding drugs to sequence-specific transcription factor-DNA complexes. J. Biol. Chem. 269,31051-31058.
• 17. Gale, E.F., Cundliffe, E., Reynolds, P.E., Richmond, M.H. & Waring, M.J. (1981) In­hibitors of nucleic acid synthesis; in The Mo­lecular Basis of Antibiotic Action; pp. 258-401, J. Wiley, N.Y.
• 18. Piestrzeniewicz, M.K., Wilmanska, D., Studz- ian, K., Szemraj,J., Czyz, M., Denny, W.A. & Gniazdowski, M. (1997) Inhibition of RNA synthesis in vitro by acridines— Relation between structure and activity. Z. Natur- forsch., in press.
• 19. Kee, A.H., Maelandsme, G.M. & Kodstad, O. (1996) Regulation of matrix metallopro teinase-1 and tissue inhibitor of metallo- proteinase-1 in MCF-7 cells: Comparison with regulatory mechanisms of pS2 expression. Clin. Exp. Metastasis 14, 381-388.
• 20. Jaros-Kamiń8ka, B., Małagocka, E., Ciesiel­ska, E. & Gniazdowski, M. (1981) Compari­son of inhibitory effect of various drugs on yeast and bacterial RNA polymerases. Studia Biophys. 86, 211-218.
• 21. Atwell, G.J., Baguley, B.C., Wilmanska, D. & Denny, W.A. (1986) Potential antitumor agents. 45. Synthesis, DNA-binding interac­tion, and biological activity of triacridine derivatives. </. Med. Chem. 29, 69-74.